NCT06339060 (PALACE3) is a Phase 3 clinical trial of Experimental: Arm 1 Organ preservation in Esophageal Cancer, sponsored by Ruijin Hospital.

Who is sponsoring NCT06339060?

NCT06339060 is sponsored by Ruijin Hospital.

What drugs are being tested in NCT06339060?

Interventions in NCT06339060: Experimental: Arm 1 Organ preservation, Active Comparator: Arm 2 Surgery.

What condition does NCT06339060 study?

NCT06339060 studies Esophageal Cancer.

Is NCT06339060 still recruiting?

NCT06339060 is currently recruiting now. Last updated 3 July 2024.

Last reviewed 2024-07-03 · How we verify

NCT06339060: PALACE3

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).

Recruiting now Phase 3 Last updated 3 July 2024

What this trial tests

Phase 3 trial testing Experimental: Arm 1 Organ preservation in Esophageal Cancer in 356 participants. Currently enrolling.

Timeline

1 May 2024

Primary endpoint
1 March 2028

1 March 2028

Quick facts

Lead sponsor	Ruijin Hospital
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	356
Start date	1 May 2024
Primary completion	1 March 2028
Estimated completion	1 March 2028
Sites	1 location across China

Drugs / interventions tested

Experimental: Arm 1 Organ preservation
Active Comparator: Arm 2 Surgery

Conditions studied

Esophageal Cancer — all drugs for Esophageal Cancer →

Sponsor

Ruijin Hospital

Who can join

Adults 18 to 75, any sex, with Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with locally advanced esophageal squamous cell carcinoma will randomly assigned to receive neoadjuvant chemo-radiotherapy combined with immunotherapy post organ preservation strategy (experimental group) or neoadjuvant chemo-radiotherapy followed by surgery (control group). The 3-year overall survival rate is the primary outcome.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Current status and perspectives of esophageal cancer: a comprehensive review.
Jiang W, Zhang B, Xu J, Xue L, et al · · 2025 · cited 28× · PMID 39723635 · DOI 10.1002/cac2.12645
Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2).
Li C, Han Y, Zhao S, Kang X, et al · · 2025 · cited 1× · PMID 41309527 · DOI 10.1038/s41392-025-02477-4
Neoadjuvant camrelizumab combined with chemoradiotherapy and watch-and-wait strategy versus neoadjuvant chemoradiotherapy followed by surgery in locally advanced oesophageal squamous cell carcinoma: study protocol of a randomised controlled trial (PALACE-3).
Wang X, Li C, Cao Y, Kang X, et al · · 2025 · PMID 41093345 · DOI 10.1136/bmjopen-2024-093538
Organ-Sparing Approach after Neoadjuvant Treatment in Oesophageal Cancer.
Pittacolo M, Khoma O, Lagarde SM, Mostert B, et al · · 2025 · PMID 40730139 · DOI 10.1159/000547632

Verify or expand the search:

Other recruiting trials for Esophageal Cancer

Currently open trials in the same condition.

NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting

Other Ruijin Hospital trials

Trials by the same sponsor.

NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06339060 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
Last refreshed: 3 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06339060.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing